About this trial
The intestinal microbiota plays an essential role in digestion and, through the gut-brain axis, in the regulation of weight gain and eating behavior. The balaEating disorders (EDs) are serious pathologies affecting adolescence and young adults, likely to become chronic, with long-term morbidity and mortality impacts. These pathologies represent a very important public health issue. EDs are defined by the DSM-V classification criteria and include different forms: anorexia nervosa, bulimia nervosa, hyperphagia, and atypical or unspecified forms. The global prevalence of these diseases reaches 8.4% in women and 2.2% in men. These eating disorders lead to numerous psychiatric and somatic complications and have a significant impact on the quality of life and mortality of patients (particularly in anorexic patients). The molecular mechanisms underlying eating disorders are still poorly understood. The etiological origin of these diseases is complex and involves various biological, psychological, and sociocultural factors. The intestinal microbiota, which corresponds to the community of microorganisms living inside the intestine, could be one of these factors. Indeed, the microorganisms of the microbiota interact very closely with intestinal cells but also with distant organs, such as the brain, via nerve communications or the bloodstream. nce and dialogue between the intestinal microbiota and human cells can be altered following changes in the environment, diet, or stress. These disturbances, found among others in patients suffering from eating disorders, can lead to a lasting change in the composition or metabolic activity of the microbiota (dysbiosis), which can have profound repercussions on human physiology. Several clinical studies conducted on patients with anorexia have highlighted the existence of intestinal dysbiosis in these individuals. As with anorexia, the potential role of intestinal dysbiosis in bulimic and binge eating patients remains currently unknown. This dysbiosis could have a harmful effect on intestinal physiology and promote the onset of functional digestive disorders, which are frequently found in patients suffering from eating disorders. This dysbiosis could also lead to a disruption of communication along the gut-brain axis and contribute to the eating disorders observed in these patients.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women.
Aged 18 to 50.
First consultation in the Nutrition Department of Rouen University Hospital for ED.
Positive SCOFF with diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder.
Disqualifiers
Men.
Aged under 18 and over 50.
Negative SCOFF.
Patients who have received antibiotic treatment in the last 3 months.
Trial population
Patients with eating disorders (ED) first-time consultants in order to limit potential interference from previous medical treatments or nutritional support and healthy volunteers not presenting with eating disorders.
Trial design
Case-only
Prospective
Treatments tested in this trial
Patients
Other interventionA clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the patients eligibility criteria to be verified. If the patient is included, the self-questionnaire will be completed on site and stool collection will be carried out.
healthy volunteer
Other interventionA clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the volunteer's eligibility criteria to be verified. If the volunteer is included, the self-questionnaire will be completed on site and stool collection will be carried out.
Treatment groups
Trial outcomes
Primary outcomes
Body weight assessment of mice receiving fecal microbiota from patients suffering from eating disorders
After collecting stool samples from the patient with eating disorders (ED) or the healthy volunteer, a suspension will be created from the stool samples of the patients or healthy volunteers. This suspension will be transplanted by oral gavage into C57Bl/6 mice whose endogenous microbiota will have been previously eliminated by the administration of antibiotics. Over time, the body weight of the transplanted animals will be evaluated. The main objective of this study is to evaluate the evolution of body weight in mice that received a fecal microbiota transplant from patients with eating disorders and to compare it with that of mice that received a microbiota transplant from healthy volunteers.
Secondary outcomes
Evaluating feeding behavior in response to microbiota transplantation from TCA patients in mice
Food and water intake will be monitored daily by weighing
Evaluating body composition in response to microbiota transplantation from TCA patients in mice
The body composition of the animals will be determined by echo-MRI (determination of fat mass and lean mass).
Evaluating the occurrence of functional digestive disorders in response to microbiota transplantation from TCA patients in mice
The occurrence of functional digestive disorders will be assessed by quantifying the efficiency of gastric emptying, the speed of intestinal transit and the water content of feces in grafted mice.
Evaluating feeding behavior in response to microbiota transplantation from healthy volunteer in mice
Food and water intake will be monitored daily by weighing
Sponsors and contacts
Click on the lead sponsor to view all of their trials.